The Rain strategy is aimed at giving patients and their families their lives back. Finding new targeted treatment options for these patients is the essence of our work. Patients are our inspiration.
Connecting with these patients helps guide us as we develop new treatment options that have the potential to be not only more effective, but preserve quality of life. It is our ultimate goal to provide patients with effective treatment options that are not characterized by the difficult side effects that are so common with most cancer treatments.
Our deep understanding of tumor biology guides each of our clinical programs. We intend to evaluate each of our therapeutic candidates not only in specific cancer types, but also in “basket trials”, where patients are eligible for the trial based on their specific tumor genetics, rather than their tumor type.
A clinical trial is a controlled study where an experimental drug or device is tested in humans. The purpose of a clinical trial is to evaluate the safety and efficacy of an experimental drug or device. To participate in a clinical trial, you must meet all eligibility criteria and be willing to follow the directions of the study doctor.
RAIN-32 Clinical Trials
RAIN-32 is an orally administered, investigational MDM2 inhibitor. We are initially evaluating RAIN-32 as a potential treatment option for a subset of patients with liposarcoma, the well differentiated / de differentiated (WD/DD) subtypes, characterized by MDM2 gene amplification. Rain commenced a Phase 3 study for patients with WD/DD liposarcoma in July 2021. For more information about the Phase 3 clinical trial, click here.
Liposarcoma is a rare cancer originating from fat cells located in the soft tissues of the body. It is a malignant cancer that can spread to other parts of the body. WD liposarcoma is less aggressive and tends to be a large painless mass found in deeper tissues. DD liposarcoma is more aggressive, arising from WD liposarcoma, and is usually found in tissue behind the abdominal area.
WD/DD liposarcoma are the most frequent subtypes of liposarcoma and share common genomic abnormalities, predominately MDM2 gene amplification. Current treatment options for liposarcoma patients are limited, and we believe inhibiting this MDM2 amplification will lead to successful tumor suppression.
Rain also intends to evaluate RAIN-32 in two additional Phase 2 trials. The first Phase 2 trial is an open-label MDM2-amplified tumor-agnostic basket trial expected to commence in the second half of 2021. A basket trial is a type of clinical trial that tests how well a new drug works in patients who have different types of cancer with the same biomarker or mutation. The second Phase 2 trial is an open-label trial in patients with intimal sarcoma, a rare sarcoma also exhibiting MDM2-amplification, expected to commence by early 2022.